Vanguard Discloses 6.09% Stake in Pacific Biosciences

TL;DR

**Vanguard still holds a big chunk of Pacific Biosciences, showing they're in it for the long haul.**

AI Summary

The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on January 10, 2024, indicating its ownership of 16,063,056 shares of Common Stock in Pacific Biosciences of California Inc. as of December 29, 2023. This represents a 6.09% passive ownership stake in the company. This filing matters to investors because it shows that a large institutional investor like Vanguard maintains a significant, albeit slightly reduced, position in Pacific Biosciences, signaling continued confidence in the company's long-term prospects.

Why It Matters

This filing confirms Vanguard's continued significant, passive investment in Pacific Biosciences, which can be seen as a vote of confidence from a major institutional investor.

Risk Assessment

Risk Level: low — This filing is routine and indicates a passive investment by a large institutional investor, posing minimal direct risk.

Analyst Insight

Smart investors should note that a large, passive institutional investor like Vanguard continues to hold a substantial stake, suggesting long-term confidence in Pacific Biosciences, but this filing alone doesn't indicate any immediate catalysts for price movement.

Key Numbers

• 16,063,056 — Shares Beneficially Owned (Represents the total number of Common Stock shares of Pacific Biosciences held by The Vanguard Group as of December 29, 2023.)
• 6.09% — Percentage of Class (Indicates the percentage of Pacific Biosciences' Common Stock that The Vanguard Group beneficially owns, showing a significant institutional stake.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Pacific Biosciences of California Inc. (company) — issuer of the securities
• 16,063,056 (dollar_amount) — number of shares beneficially owned by Vanguard
• 6.09% (dollar_amount) — percentage of class beneficially owned by Vanguard
• December 29, 2023 (date) — date of event requiring the filing

Forward-Looking Statements

• Vanguard will maintain a significant, passive stake in Pacific Biosciences for the foreseeable future. (The Vanguard Group) — high confidence, target: 2025-12-31

FAQ

From the Filing

0001104659-24-002867.txt : 20240110 0001104659-24-002867.hdr.sgml : 20240110 20240110101657 ACCESSION NUMBER: 0001104659-24-002867 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-85738 FILM NUMBER: 24525251 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: VANGUARD GROUP INC CENTRAL INDEX KEY: 0000102909 ORGANIZATION NAME: IRS NUMBER: 231945930 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 BUSINESS PHONE: 6106691000 MAIL ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 SC 13G/A 1 tv0020-pacificbiosciencesofc.htm SCHEDULE 13G/A pacificbiosciencesofcaliforniainc SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer:  Pacific Biosciences of California Inc Title of Class of Securities:  Common Stock CUSIP Number:  69404D108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on the following page(s))     13G CUSIP No.:  69404D108 1.  NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON The Vanguard Group - 23-1945930 2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP A.  B.  X 3.  SEC USE ONLY 4.  CITIZENSHIP OF PLACE OF ORGANIZATION Pennsylvania (For questions 5-8, report the number of shares beneficially owned by each reporting person with:) 5.  SOLE VOTING POWER 0 6.  SHARED VOTING POWER 325,985 7.  SOLE DISPOSITIVE POWER 26,204,812 8.  SHARED DISPOSITIVE POWER 584,687 9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 26,789,499 10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES N/A 11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 10.02% 12.  TYPE OF REPORTING PERSON IA     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Act of 1934 Item 1(a) - Name of Issuer: Pacific Biosciences of California Inc Item 1(b) - Address of Issuer's Principal Executive Offices: 1305 O'Brien Drive Menlo Park, CA 94025 Item 2(a) - Name of Person Filing: The Vanguard Group - 23